CORT RSI Chart
Last 7 days
5.5%
Last 30 days
7.9%
Last 90 days
-25.2%
Trailing 12 Months
12.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 413.8M | 428.2M | 450.0M | 482.4M |
2022 | 380.2M | 392.0M | 397.6M | 401.9M |
2021 | 340.1M | 343.1M | 352.9M | 366.0M |
2020 | 334.9M | 351.2M | 356.0M | 353.9M |
2019 | 258.4M | 268.4M | 285.4M | 306.5M |
2018 | 189.3M | 216.0M | 237.7M | 251.2M |
2017 | 92.9M | 108.7M | 129.7M | 159.2M |
2016 | 56.2M | 64.0M | 72.5M | 81.3M |
2015 | 32.2M | 38.4M | 44.3M | 50.3M |
2014 | 13.0M | 17.0M | 21.7M | 26.6M |
2013 | 5.0M | 6.0M | 7.6M | 10.4M |
2012 | 2.4M | 2.7M | 3.0M | 3.3M |
2011 | 0 | 0 | 1.8M | 2.1M |
2010 | 0 | 566.0K | 1.0M | 1.5M |
2009 | 0 | 0 | 0 | 101.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 19, 2024 | maduck sean | acquired | 26,100 | 2.61 | 10,000 | see remarks |
Mar 18, 2024 | maduck sean | sold | -430,475 | 25.00 | -17,219 | see remarks |
Mar 18, 2024 | maduck sean | acquired | 66,809 | 3.88 | 17,219 | see remarks |
Mar 01, 2024 | maduck sean | sold (taxes) | -12,150 | 24.06 | -505 | see remarks |
Mar 01, 2024 | swisher daniel n jr | acquired | 12,892 | 5.86 | 2,200 | - |
Mar 01, 2024 | lyon joseph douglas | sold (taxes) | -11,404 | 24.06 | -474 | chief accounting officer |
Mar 01, 2024 | robb gary charles | sold (taxes) | -15,783 | 24.06 | -656 | chief business officer |
Mar 01, 2024 | mokari atabak | acquired | 13,329 | 12.03 | 1,108 | chief financial officer |
Mar 01, 2024 | guyer william | sold (taxes) | -14,532 | 24.06 | -604 | chief development officer |
Mar 01, 2024 | robb gary charles | acquired | 16,769 | 12.03 | 1,394 | chief business officer |
Which funds bought or sold CORT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | added | 28.36 | 123,887 | 357,540 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 2.58 | 56,464,700 | 309,779,000 | 0.01% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 160 | 23,476,500 | 34,608,100 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.88 | 220,395 | 1,433,340 | 0.01% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -227,000 | - | -% |
Feb 26, 2024 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 161,000 | 1,005,000 | 0.01% |
Feb 26, 2024 | SYON CAPITAL LLC | new | - | 204,851 | 204,851 | 0.02% |
Feb 26, 2024 | Neo Ivy Capital Management | sold off | -100 | -66,000 | - | -% |
Feb 23, 2024 | CIM, LLC | new | - | 359,794 | 359,794 | 0.06% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 5.85 | 347,000 | 1,674,000 | -% |
Unveiling Corcept Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Peers (Alternatives to Corcept Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Corcept Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 9.6% | 135 | 124 | 118 | 106 | 103 | 102 | 103 | 94.00 | 99.00 | 96.00 | 92.00 | 79.00 | 86.00 | 86.00 | 89.00 | 93.00 | 88.00 | 82.00 | 72.00 | 65.00 | 67.00 |
Costs and Expenses | 12.2% | 104 | 92.00 | 88.00 | 91.00 | 81.00 | 70.00 | 72.00 | 67.00 | 62.00 | 60.00 | 60.00 | 60.00 | 55.00 | 62.00 | 53.00 | 56.00 | 53.00 | 49.00 | 48.00 | 46.00 | 42.00 |
S&GA Expenses | 4.2% | 47.00 | 45.00 | 43.00 | 49.00 | 42.00 | 35.00 | 38.00 | 38.00 | 32.00 | 31.00 | 30.00 | 30.00 | 26.00 | 27.00 | 26.00 | 28.00 | 27.00 | 24.00 | 25.00 | 24.00 | 22.00 |
R&D Expenses | 20.2% | 55.00 | 46.00 | 43.00 | 41.00 | 37.00 | 33.00 | 33.00 | 28.00 | 29.00 | 28.00 | 28.00 | 29.00 | 28.00 | 34.00 | 26.00 | 26.00 | 24.00 | 23.00 | 22.00 | 20.00 | 19.00 |
EBITDA Margin | 3.6% | 0.26* | 0.25* | 0.26* | 0.26* | 0.29* | 0.33* | 0.33* | 0.35* | 0.34* | 0.34* | 0.32* | 0.33* | - | - | - | - | - | - | - | - | - |
Income Taxes | 9.2% | 5.00 | 5.00 | 5.00 | 3.00 | 8.00 | -1.60 | 5.00 | 4.00 | 5.00 | 6.00 | 6.00 | -3.60 | 5.00 | 4.00 | 8.00 | 9.00 | 7.00 | 8.00 | 6.00 | 2.00 | 4.00 |
Earnings Before Taxes | 1.2% | 37.00 | 36.00 | 33.00 | 18.00 | 24.00 | 33.00 | 32.00 | 27.00 | 37.00 | 36.00 | 32.00 | 20.00 | 31.00 | 25.00 | 36.00 | 39.00 | 36.00 | 34.00 | 26.00 | 20.00 | 26.00 |
EBT Margin | 3.7% | 0.26* | 0.25* | 0.25* | 0.26* | 0.29* | 0.32* | 0.34* | 0.35* | 0.34* | 0.34* | 0.32* | 0.33* | - | - | - | - | - | - | - | - | - |
Net Income | -0.1% | 31.00 | 31.00 | 28.00 | 16.00 | 17.00 | 35.00 | 27.00 | 23.00 | 32.00 | 30.00 | 27.00 | 23.00 | 26.00 | 22.00 | 28.00 | 30.00 | 29.00 | 26.00 | 20.00 | 18.00 | 22.00 |
Net Income Margin | 8.4% | 0.22* | 0.20* | 0.22* | 0.23* | 0.25* | 0.29* | 0.29* | 0.29* | 0.31* | 0.30* | 0.28* | 0.29* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -88.9% | 6.00 | 53.00 | 42.00 | 26.00 | 33.00 | 33.00 | 18.00 | 35.00 | 49.00 | 49.00 | 44.00 | 25.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 4.6% | 622 | 594 | 525 | 618 | 583 | 533 | 496 | 468 | 424 | 585 | 568 | 552 | 572 | 534 | 498 | 445 | 412 | 367 | 329 | 320 | 312 |
Current Assets | 6.3% | 459 | 432 | 433 | 534 | 499 | 452 | 419 | 388 | 266 | 402 | 411 | 410 | 479 | 463 | 438 | 345 | 307 | 267 | 233 | 217 | 237 |
Cash Equivalents | 21.2% | 136 | 112 | 172 | 300 | 66.00 | 50.00 | 35.00 | 62.00 | 78.00 | 95.00 | 95.00 | 52.00 | 76.00 | 31.00 | 59.00 | 84.00 | 31.00 | 45.00 | 58.00 | 50.00 | 42.00 |
Inventory | 2.9% | 8.00 | 8.00 | 7.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
Net PPE | -35.4% | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -13.2% | 115 | 132 | 103 | 88.00 | 82.00 | 60.00 | 54.00 | 60.00 | 48.00 | 45.00 | 46.00 | 42.00 | 48.00 | 44.00 | 44.00 | 36.00 | 41.00 | 33.00 | 31.00 | 34.00 | 36.00 |
Current Liabilities | -14.3% | 105 | 122 | 93.00 | 79.00 | 72.00 | 53.00 | 49.00 | 57.00 | 48.00 | 45.00 | 45.00 | 41.00 | 47.00 | 43.00 | 42.00 | 34.00 | 39.00 | 32.00 | 30.00 | 34.00 | 36.00 |
Shareholder's Equity | 9.8% | 507 | 462 | 422 | 530 | 502 | 473 | 442 | 408 | 376 | 540 | 523 | 511 | 523 | 490 | 454 | 409 | 371 | 334 | 298 | 286 | 276 |
Retained Earnings | 8.4% | 403 | 371 | 340 | 312 | 296 | 280 | 245 | 218 | 195 | 163 | 132 | 106 | 82.00 | 56.00 | 35.00 | 7.00 | -23.55 | -52.94 | -79.28 | -99.46 | -117 |
Additional Paid-In Capital | 2.2% | 739 | 722 | 696 | 680 | 662 | 649 | 626 | 609 | 591 | 571 | 554 | 536 | 516 | 496 | 482 | 466 | 457 | 447 | 437 | 427 | 417 |
Shares Outstanding | -0.5% | 103 | 104 | 105 | 108 | 108 | 107 | 106 | 106 | 116 | 116 | 117 | 117 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 1,827 | - | - | - | 2,058 | - | - | - | 2,122 | - | - | - | 1,633 | - | - | - | 1,071 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -88.9% | 5,887 | 52,909 | 42,286 | 25,957 | 33,388 | 33,648 | 18,040 | 35,247 | 49,427 | 48,704 | 44,339 | 25,422 | 35,071 | 30,444 | 53,186 | 33,269 | 48,454 | 38,427 | 25,555 | 23,681 | 21,519 |
Share Based Compensation | 1.5% | 13,065 | 12,876 | 11,858 | 11,141 | 10,521 | 10,554 | 10,606 | 10,761 | 10,810 | 10,952 | 11,068 | 10,101 | 8,430 | 8,702 | 8,489 | 7,918 | 7,610 | 7,271 | 7,736 | 6,696 | 6,266 |
Cashflow From Investing | 115.6% | 17,098 | -109,570 | -24,097 | 207,475 | -17,241 | -4,790 | -41,800 | -50,496 | 140,471 | -25,803 | 24,742 | -3,284 | 11,220 | -64,273 | -85,944 | 19,734 | -61,989 | -54,316 | -1,156 | -367 | -1,757 |
Cashflow From Financing | 119.6% | 766 | -3,916 | -145,754 | 181 | -61.00 | -13,961 | -2,756 | -506 | -206,969 | -23,643 | -26,032 | -45,947 | -661 | 5,866 | 6,804 | 205 | -144 | 2,696 | -15,908 | -15,289 | -12,031 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | 25,774 | 29,170 | 33,541 | 9,670 | - | - | 275 | - | - | 17,420 | 13,555 | 14,753 |
CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Product revenue, net | $ 482,375 | $ 401,858 | $ 365,978 |
Operating expenses: | |||
Cost of sales | 6,481 | 5,385 | 5,281 |
Research and development | 184,353 | 130,991 | 113,864 |
Selling, general and administrative | 184,259 | 152,848 | 122,356 |
Settlement expense related to Melucci litigation | 0 | 14,000 | 0 |
Insurance recovery related to Melucci litigation | 0 | (14,000) | 0 |
Total operating expenses | 375,093 | 289,224 | 241,501 |
Income from operations | 107,282 | 112,634 | 124,477 |
Interest and other income | 17,275 | 3,557 | 529 |
Income before income taxes | 124,557 | 116,191 | 125,006 |
Income tax expense | (18,417) | (14,773) | (12,494) |
Net income | 106,140 | 101,418 | 112,512 |
Net income attributable to common stockholders, basic | 105,496 | 101,288 | 112,512 |
Net income attributable to common stockholders, diluted | $ 105,496 | $ 101,288 | $ 112,512 |
Basic net income per share (in dollars per share) | $ 1.02 | $ 0.95 | $ 0.97 |
Diluted net income per share (in dollars per share) | $ 0.94 | $ 0.87 | $ 0.89 |
Weighted-average shares outstanding used in computing net income per common share | |||
Basic (in shares) | 103,560 | 106,787 | 115,653 |
Diluted (in shares) | 111,742 | 115,966 | 125,963 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 135,551 | $ 66,329 |
Short-term marketable securities | 232,670 | 365,343 |
Trade receivables, net of allowances | 41,123 | 31,057 |
Insurance recovery receivable related to Melucci litigation (Note 10) | 14,000 | 14,000 |
Inventory | 7,730 | 6,100 |
Prepaid expenses and other current assets | 27,562 | 16,424 |
Total current assets | 458,636 | 499,253 |
Strategic inventory | 8,244 | 10,931 |
Operating lease right-of-use asset | 120 | 1,143 |
Property and equipment, net of accumulated depreciation and amortization | 195 | 633 |
Long-term marketable securities | 57,176 | 4,947 |
Other assets | 6,541 | 5,058 |
Deferred tax assets, net | 90,605 | 61,465 |
Total assets | 621,517 | 583,430 |
Current liabilities: | ||
Accounts payable | 17,396 | 11,976 |
Accrued research and development expenses | 21,330 | 14,573 |
Accrued and other liabilities | 51,628 | 30,799 |
Accrued settlement related to Melucci litigation (Note 10) | 14,000 | 14,000 |
Short-term operating lease liability | 151 | 1,143 |
Total current liabilities | 104,505 | 72,491 |
Long-term accrued income taxes payable | 10,307 | 9,097 |
Total liabilities | 114,812 | 81,588 |
Commitments and contingencies (Note 10) | ||
Stockholders’ equity: | ||
Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 2022 | 0 | 0 |
Common stock, par value $0.001 per share, 280,000 shares authorized and 134,344 issued and 103,405 outstanding as of December 31, 2023 and 130,959 shares issued and 107,835 outstanding as of December 31, 2022 | 133 | 131 |
Treasury stock; at cost; 30,938 shares of common stock as of December 31, 2023 and 23,124 shares of common stock as of December 31, 2022 | (635,078) | (456,148) |
Additional paid-in capital | 738,515 | 662,342 |
Accumulated other comprehensive income (loss) | 609 | (869) |
Retained earnings | 402,526 | 296,386 |
Total stockholders’ equity | 506,705 | 501,842 |
Total liabilities and stockholders’ equity | $ 621,517 | $ 583,430 |